Biogen Inc News - BIIB

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO:...

Form 4 - Statement of changes in beneficial ownership of securities

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up

U.S. index futures rose slightly in Wednesday’s pre-market as traders assessed Alphabet (NASDAQ:GOOGL)’s...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

CAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Michael...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment...

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data...

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA...

Monksdream 3 weeks ago

BIIB new 52 week low

👍️0

tredenwater2 1 month ago

Biib must be out of AD bullets…or actually more like BB’s. With 3-4 20 billion dollar swap trading by HF’s the stock is at multiyear lows. It used to hit $200 and would spring up like clock work.

I hope the validation of our science upon MAA approval at AVXL puts a fork in this company making their pipeline overly insignificant.

👍️0

Monksdream 4 months ago

BIIB still in bear mode

👍️0

avxl_going_long 6 months ago

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

👍️0

Monksdream 7 months ago

BIIB still in bear mode

👍️0

Lonewolf1 2 years ago

Oops…. Another HOD

$10

👍️0

MiamiGent 2 years ago

BIIB Took a little short AH when it's PDUFA decision was mixed
Shorted at 261.50
Closed out AH at 260.87
Not expecting more than a hamburger and fries. BIOGEN INC is huge company and hard to move its dial.

https://stockcharts.com/h-sc/ui?s=BIIB

👍️0

Mr. Zen 2 years ago

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

👍️0

Mr. Zen 2 years ago

This board is about to light up!

👍️0

tredenwater2 2 years ago

Well Biib and Esaly look to be joined at the hip. And here I thought they were two profitable independent companies. Amazing how they have traded virtually identical as if this is their only ticket left to punch.

And why no run up? Is the gig finally up Mc? Maybe their MM “cried wolf” one too many times.

👍️0

McMagyar 2 years ago

Who wants to be the lead Buffalo today?
Can you stampede the herd of bio thieves over the $30Billion dollar cliff for the fourth time? Maybe! But you are stealing from treatments and patients and all those who love them.. for nothing..
The best aduscam will ever be is an adjuvant to anavex or cassava..

The BEST..

Don’t do it again .. even if you can..

Please

👍️0

tredenwater2 2 years ago

Funds swapping spit again, nothing new.

👍️0

McMagyar 2 years ago

Imagine if fda had denied?
Pyrrhic Victory defined

👍️0

tredenwater2 2 years ago

Amen MC. Im surprised at only a 3.5% rise in pps. Wheres the 10-20 billion MC increase enthusiasm like 4 times before? Maybe they will have to PR it again in a week so the market “gets it”.

👍️0

McMagyar 2 years ago

Ps not short Biogen..
Just long dementia

👍️ 1

McMagyar 2 years ago

Investors can make a difference as to what our healthcare system becomes..

You and your decisions affect millions of lives..

Let Blarcamesine , succesful TLD ,
Be the rule of the day for our sick..

See if other drugs help people once their homeostasis is secured..maybe in smaller doses as an adjuvant ..

Anavex’s Blarcamesine works

👍️0

McMagyar 2 years ago

If you will give a healthy 5 year old an experimental mRNA drug which creates toxic spike proteins in their system..by design! Nonetheless, why wouldn’t you give death sentenced dementia patients a dangerous possibly brain swelling drug that does almost nothing?

The system is broken

👍️0

McMagyar 2 years ago

This will be the last chance to extricate your financial future from bioscam
And invest in one of these :
Anavex
Cassava
Annovis

Biovie

In that order of magnitude per solution and timing ..in my humble opinion

Or all four..

👍️0

tredenwater2 2 years ago

Will Biogen drop like a rock by or shoot up by 10 billion come Friday? FDA is in a pickle here. Is there an advisory panel this go around or is this who will weigh in come Friday?

👍️0

tredenwater2 2 years ago

What a scam! Older article but will take afew years to play out Im sure.

👍️0

tradeherpete 2 years ago

Biogen Accused of Baiting Patients With Illegal Drug Co-Pays
ByRobert Burnson
September 24, 2021, 9:57 PM EDT

Biogen Inc. was accused by a managed-care provider of illegally boosting sales of its pricey multiple sclerosis drugs by providing them free to patients on a temporary basis and then funneling money to them for co-payments so they can keep taking the medications.

The first part of the scheme involves “seeding” the drugs -- Tysabri, Avonex, and Tecfidera -- to multiple sclerosis sufferers who lacked medical insurance, according to the lawsuit filed Friday by Humana Inc.

After a few months, Biogen encourages the patients to sign up for government-funded healthcare and then funnels “illegal copayment assistance to those same patients under the guise of unrestricted charitable giving,” Humana said.

The money is funneled through a large specialty pharmacy and two medical charities who provide co-pay assistance, according to the suit.

“Given the high costs of the MS drugs here, copays can be thousands of dollars for any single patient,” Humana says in the suit.“But they are a tiny fraction of the total expense for the drugs. This means that if the manufacturer pays the copays itself, it can earn a major return from a minor investment.”

The drugs cost $50,000 to $80,000 a year, according to the suit.

Biogen didn’t respond after regular business hours to a request for comment.

👍️0

Dennisb68 2 years ago

RGEN is on a run while Biogen is stalled.. Both similar companies,

👍️0

jgrabar 2 years ago

https://www.marketwatch.com/press-release/grabar-law-office-investigates-claims-on-behalf-of-shareholders-of-biogen-inc-biib-after-it-agrees-to-pay-900-million-for-improper-physician-payments-2022-11-30?siteid=bigcharts&dist=bigcharts&tesla=y

👍️0

tredenwater2 2 years ago

Unlike the patients heads, the share price “swelling” for Biogen always goes down. Another difference is Biogens Alzheimer’s amyloid platform never dies, just a few of their patients here and there in their trials.

Alzheimer’s is tough, didnt you know, just a little collateral damage, now hurry up and give me approval!

👍️0

McMagyar 2 years ago

How does this dead dog bounce?
On swelled brains of course

👍️0

blackpilled 2 years ago

One last dance?

👍️0

McMagyar 3 years ago

Wouldnt touch bioscam
But agree seller salmoat out

👍️0

conix 3 years ago

Biogen (NASDAQ:BIIB) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $265.00 price target on the stock, up previously from $235.00.This represents a 23.7% upside from the current price of $214.28

---- Biotechs are due for a run soon....jmo

👍️0

McMagyar 3 years ago

Phase 4. How many must suffer to pave the linings? When anavex has safe and proved drug available now?
How hateful the crews that say they care about human beings suffering dementia..

You don’t give a shit

👍️0

McMagyar 3 years ago

Can you imagine the poor bastards that listened to Corey Renauer of motley fool when he said sell Anavex and buy Biogen a few years back?
Can they sue anyone?

What a cruel and twisted effort that was

👍️0

McMagyar 3 years ago

All the resources these pumpers stole from legitimate chances to save people with dementia..

How much quicker Anavex and others could have moved without this blockaded fraud in their way..

Oxygen and money hole from hell

👍️0

McMagyar 3 years ago

Thought they were getting bought out today?

What’s worse is

They knew who anavex was and blew up a chance at a deep relationship through what appears to be a poorly handled MTA ..

Still waiting for Wayne State.. pathetic really..

Arrogance and power smell worse than week old sub Saharan carrion..

👍️0

tredenwater2 3 years ago

Another pump and dump, this time on approval of their drug of all things! Wow, when even approval doesnt work there is some real bad mojo working against you. 3rd or 4 rth cycle of 20 billion that has come and gone. The HFs that own BIIB are making a killing, no pun intended!

👍️0

AAAAMHIM 3 years ago

$BIIB NEWS!!!! Fasten your SEATBELTS!???????
https://finance.yahoo.com/news/biogen-plans-initiate-phase-3b-113000162.html

👍️0

EHRjunkie 3 years ago

Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on

https://www.accesswire.com/viewarticle.aspx?id=663682

👍️0

tredenwater2 3 years ago

Laughable, the pps is one step away from giving up all the fake gains from the announcement of Fda approval for their drug which is still not shown to be efficacious and can be highly toxic for patients including but not limited to death.

OAN Im a little surprised that ihub only allows investors to go back 1 year on the charting….. what gives? Those that forget history are more likely to repeat it. Case in point, I was trying to go back 5 years and look at how Biogen has been overhyped now 3 times for the very close to the exact same amount and has given it all back 2 of the 3 and soon to be 3 for 3 times.

Just an observation.

👍️0

mrplmer 3 years ago

Pps down $120+ after pumping their bad meds which have no efficacy. Eisai has to break away or go down with the liars. Japanese dont like the bad rep.

👍️0

conix 3 years ago

STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

By Ed Silverman

The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration.

👍️0

Pioneer10257 3 years ago

Biogen's Aduhelm stumbles at the starting blocks.

https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/

Chilean spy 3 years ago

Hi Mrplmer
This company's lack of evidence for it's drug' safety and effectiveness should plunge the stock to nothing I wonder what s keeping it on the 300 hundreds. Everyday's bad news around then and it keeps going up ?

👍️0

mrplmer 3 years ago

It doesntcome close to Anavex results.

👍️0

AAAAMHIM 3 years ago

CLOSED EXTREMELY BULLISH INTO close and afterhours. I wouldnt wanna be a short tomorrow.

Listen to a $BIIB patient who's A DOCTOR! MUST WATCH VIDEO. DRUG WORKS! Poor shorts lost their ONLY ammo to bash it. Their KEY bash has expired, now they're reaching for anything. $BIIB can run for a full week+ shorts will lose houses here. Will run $600+.
https://t.co/1xX3cNoMCk

👍️0

mrplmer 3 years ago

Down 100 pts since they released the dog. FDA needs to redeem themselves from passing on this POS onto the public.

👍️0

tradeherpete 3 years ago

The fallout has already been widespread. So far, three members of the FDA’s advisory committee have resigned, one of them calling the process a “sham.” Doctors who helped run Biogen’s clinical studies are speaking out, and others are penning editorials that they won’t be prescribing Aduhelm until they see evidence of effectiveness. But no one should hold their breath. When the FDA greenlit Aduhelm for use, it told Biogen it had nine years to run the confirmatory studies necessary to prove Aduhelm’s effectiveness. Nine years of people taking this drug that existing data suggests might not do anything meaningful. With Aduhelm poised to become among the biggest blockbuster drug in history—analysts estimate annual revenues could peak at $10 billion—Biogen probably isn’t in a hurry. But they might not even have to collect that extra data at all (for its part, Biogen said in an email to Slate, “We are working diligently to initiate the confirmatory trial”). Ross, the Yale FDA regulatory expert, looked at FDA approvals from 2005–12, and found that post-market confirmatory studies—ones that truly verified the clinical value of a surrogate outcome—only took place about 10 percent of the time. Despite this dismal compliance rate, according to Ross, the FDA has never fined a company for failing to do a confirmatory study and rarely uses its power to withdraw a drug later shown to be clinically ineffective. In an email to Slate, the FDA did not offer comment on whether it would use its power to withdraw Aduhelm should the drug ultimately prove clinically ineffective but “will carefully monitor trial progress and support efforts to complete this trial in the shortest possible timeline.”

https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp

👍️0

polarbear77 3 years ago

https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp

#pathetic

👍️0

mrplmer 3 years ago

This is a POS. Puts lipstick on pigs and makes drugs that cause brain bleeds.

👍️0

hebbeke47 3 years ago

https://endpts.com/new-alzheimers-drug-approval-fallout-public-citizen-seeks-removal-of-fdas-woodcock-cavazzoni-and-dunn/

👍️0

Cbdpotential 3 years ago

https://www.facebook.com/752348178140245/posts/4973596112682076/?d=n

👍️0

Cbdpotential 3 years ago

http://bit.ly/2O37FjH

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Biogen Inc (BIIB)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BIIB News

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

BIIB Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Biogen Inc (BIIB) News

Biogen Inc (BIIB)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BIIB News

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

BIIB Discussion

Your Recent History

Company

Business

Popular

Get The App